apocell Home Contact Us

Rare cells. Significant results.

ApoCell utilizes state-of-the-art technologies for analysis of rare cell populations. Enriching for a specific rare population from whole blood for downstream molecular or protein analysis yields valuable information on pharmacodynamics and subset phenotype, and even may allow for patient stratification. ApoCell currently incorporates methods of highly sensitive immunomagnetic enrichment into studies requiring the isolation of a population of interest for the analysis.

Circulating Tumor Cells
Circulating Endothelial Cells
Stem Cells
Custom Isolation 

rare cells

Novel methods are being developed to enhance the sensitivity of recovery of specific rare cell populations, including antigen-independent methods which will allow for enrichment of cells based on physical characteristics.

Circulating Tumor Cells

ApoCell is an authorized service provider for the Veridex CellSearch® CTC IVD test. The sensitivity, specificity and reproducibility of CellSearch® allows for rapid observation of changes of CTC counts as early as the first cycle of treatment to help evaluate patient progression earlier. Apocell has taken enumeration of CTCs a step further by significantly improving recovery rate, thus allowing for downstream biomarker and molecular analysis of CTCs. ApoCell incorporates its enhanced CTC recovery process in ongoing clinical studies assessing biomarkers in CTCs to determine parameters such as stratification of patients, drug efficacy, and clinical correlation to tumor phenotype.

circulating tumor cells

Circulating Endothelial Cells

Circulating endothelial cells (CECs) are increasingly studied as surrogate biomarkers in many cases of cancers undergoing anti-angiogenic therapy. Isolation of the CEC population and stratification of the maturity level is achieved by immunomagnetic enrichment based on a broadly-expressed surface marker, such as CD31 or CD146, coupled to more specific analysis of CD105, the vascular endothelial growth factor receptors (VEGFRs), or others. Induction of apoptosis within the CEC population has also shown to be a very valuable measurement, whereby cell death caused by anti-angiogenesis treatment can be gauged. ApoCell performs phenotyping analysis of the enriched population to meet the needs of the client and provides consultation to define the options best suited for the disease state or targeted therapy.

circulating endothelial cells

Stem Cells

Stem cell research is a rapidly expanding area of investigation. It is well known that hematopoietic stem cells (HSCs) can be defined, isolated, and utilized for gaining mechanism insight of stem cell growth and differentiation, as well as stem cell use for tissue engineering applications.

The hematopoietic stem cells can be enriched from peripheral blood by immunomagnetic enrichment based on CD34 antigen, further stained for other markers, and followed by Multiplex Flow Cytometry and/or LSC quantification. ApoCell offers a variety of different antigen combination analysis that includes combinations of CD34 with other markers such as CD45 and CD15.

ApoCell isolates the rare cell populations and further phenotypes the cell populations based on protein expression or molecular analysis. These analyses may reveal efficacy of a therapy by successful inhibition of its targeted pathway or receptor, or by quantification of frequency of cancer or tumor stem cells. In anti-vasculogenesis therapies, circulating endothelial progenitor cells may be similarly enriched, quantified and analyzed for this relevant therapeutic target population.

Custom Isolation

Development of projects to identify other target rare cell populations of interest for downstream analysis is currently being implemented and customized to suit each client’s needs. ApoCell’s methodology results in high specificity with superior recovery rates, allowing for the most relevant enriched population to be obtained. Some potential enrichment markers used include:

  • Endothelial Cells
  • Epithelial Cells
  • Stem and Progenitor Cells
  • Growth Factor Receptor Expressing Cells
  • Cytokeratin Expressing Cells
  • Cells Expressing Disease-Specific Proteins
  • Multiple Target Cell Enrichment